T 89

Drug Profile

T 89

Alternative Names: Cardiotonic Pills; Compound Danshen Dripping Pills; Danshen Plus; Dantonic Capsule; Salvtonic; T89; Tasly Danshen Plus Capsule

Latest Information Update: 06 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tianjin Tasly Pharmaceutical
  • Developer Tasly Pharmaceutical Group; Tasly Pharmaceuticals, Inc.
  • Class Herbal medicines; Ischaemic heart disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Angina pectoris
  • Phase III Diabetic retinopathy
  • Phase I/II Respiration disorders

Most Recent Events

  • 13 Jul 2017 Tasly Pharmaceuticals completes a phase I/II trial in Respiration disorders (In volunteers) in China (NCT03270787)
  • 01 Dec 2016 Tasly Pharmaceuticals completes a phase III trial in Angina pectoris in USA, Belarus, Georgia, Mexico, Ukraine, Russia and Canada (PO) (NCT01659580)
  • 01 May 2013 Phase-III clinical trials in Diabetic retinopathy in China (PO) (NCT02388984)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top